PLUS THERAPEUTICS, Inc. - Common Stock (NQ:PSTV)

0.2400 -0.0100 (-4.00%)

Streaming Delayed Price Updated: 2:03 PM EST, Jan 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PLUS THERAPEUTICS, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Insiders Buying Plus Therapeutics And 2 Other Stocks Under $2 ↗

November 09, 2023

The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Why Plus Therapeutics Stock Popped Today ↗

November 01, 2023

PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday.

Via Benzinga

Why Extreme Networks Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

November 01, 2023

Gainers

Via Benzinga

Earnings Outlook For Plus Therapeutics ↗

October 30, 2023

Via Benzinga

Plus Therapeutics Earnings Preview ↗

August 11, 2023

Via Benzinga

HC Wainwright & Co. Maintains Buy Rating for Plus Therapeutics: Here's What You Need To Know ↗

June 30, 2023

Via Benzinga

Why Plus Therapeutics Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket ↗

November 01, 2023

Gainers

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 01, 2023

We're starting off Wednesday with a breakdown of the biggest pre-market stock movers investors will want to keep track of today!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

October 31, 2023

Via Benzinga

Earnings Scheduled For October 31, 2023 ↗

October 31, 2023

Companies Reporting Before The Bell • BBVA (NYSE:BBVA) is likely to report earnings for its third quarter. • BP (NYSE:BP) is expected to report quarterly earnings at $1.37 per share on revenue of...

Via Benzinga

Why Is Liquid Biopsy Firm Biocept Stock Trading Lower Today? ↗

October 16, 2023

Biocept Inc (NASDAQ: BIOC) filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.

Via Benzinga

Topics Bankruptcy

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 29, 2023

Via Benzinga

Plus Therapeutics And 2 Other Stocks Under $2 Insiders Are Buying ↗

September 18, 2023

The Dow Jones closed lower by close to 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...

Via Benzinga

Topics Stocks

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

September 11, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 08, 2023

Via Benzinga

Why Is Cancer Diagnostic Focused Biocept Stock Trading Higher Today? ↗

September 08, 2023

Biocept Inc (NASDAQ: BIOC) shares are trading higher after the company signed a non-exclusive licensing agreement for CNSide with Plus Therapeutics Inc (NASDAQ: PSTV), which expands the comprehensive...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

September 08, 2023

Pre-market stock movers are a hot topic worth checking out on Friday with a look at the biggest winners and losers today!

Via InvestorPlace

EXCLUSIVE: Cancer Firm Plus Therapeutics Licenses Diagnostic Assay To Detect Central Nervous System Cancers ↗

September 08, 2023

Plus Therapeutics Inc (NASDAQ: PSTV) has expanded its supply agreement with Biocept Inc (NASDAQ: BIOC) by acquiring an option to exclusively license Biocept's CNSide, a cerebrospinal flu

Via Benzinga

Plus Therapeutics Presents Exciting New Clinical Data At Top Cancer Conference ↗

August 14, 2023

Marc Hedrick, President & CEO of Plus Therapeutics (NASDAQ: PSTV), was a guest on Benzinga’s All-Access.

Via Benzinga

Why Maxeon Solar Technologies Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

August 11, 2023

Gainers Amyris, Inc. (NASDAQ: AMRS) shares jumped 179.1% to $0.1839. Amyris shares dipped over 80% on Thursday after the company announced it filed for Chapter 11 bankruptcy.

Via Benzinga

Topics Bankruptcy

Earnings Scheduled For August 14, 2023 ↗

August 14, 2023

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.

Via Benzinga

EXCLUSIVE: Plus Therapeutics Lead Candidate Shows Preliminary Safety, Efficacy In Type Of Brain Cancer ↗

August 11, 2023

Plus Therapeutics Inc (NASDAQ: PSTV) reported data from the ReSPECT-LM study evaluating the company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 26, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 25, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 24, 2023

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 05, 2023

Via Benzinga

Plus Therapeutics Releases Early-Cut Data From Cancer Studies For Brain Cancer Settings ↗

June 29, 2023

Plus Therapeutics Inc (NASDAQ: PSTV) reported interim updates from the ReSPECT-GBM and ReSPECT-LM studies of rhenium (186Re) obisbemeda, for recurrent glioblastoma (rGBM)

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

June 29, 2023

Via Benzinga

Plus Therapeutics – Precision Radiology Is Proving Highly Effective At Fighting Cancer ↗

June 26, 2023

Marc Hedrick, M.D., President and CEO of Plus Therapeutics (NASDAQ: PSTV) was recently a guest on Benzinga’s All-Access.

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.